<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564018</url>
  </required_header>
  <id_info>
    <org_study_id>UTSW-052006-056</org_study_id>
    <secondary_id>GCRC Protocol #816</secondary_id>
    <nct_id>NCT00564018</nct_id>
  </id_info>
  <brief_title>Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH</brief_title>
  <official_title>Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether using a long-acting insulin analog at the time of diagnosis, instead of
      intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin
      in children with newly diagnosed type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Presumed loss of clinical equipoise between the agents being investigated
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide area under the curve in response to a mixed meal tolerance test 6 months after diagnosis of diabetes.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic control as determined by HgbA1c values at quarterly intervals after diagnosis of diabetes.</measure>
    <time_frame>Quarterly for 12 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Detemir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin detemir</intervention_name>
    <description>Dosage adjusted to meet age-specific glycemic goals throughout course of study.</description>
    <arm_group_label>Detemir</arm_group_label>
    <other_name>Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.</description>
    <arm_group_label>Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH</intervention_name>
    <description>Dosage to be adjusted to meet age specific glycemic goals throughout course of study.</description>
    <arm_group_label>NPH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed type 1 diabetes within 1 week of diagnosis

          -  Age 6 - 18 years

          -  Care provided at Children's Medical Center, Dallas

        Exclusion Criteria:

          -  Actual treatment with oral drugs influencing beta cell function or blood glucose
             levels (e.g. oral hypoglycemic agents)

          -  Actual treatment with drugs influencing insulin sensitivity (e.g. Metformin, or
             systemic steroids)

          -  Significant concomitant disease likely to interfere with glucose metabolism (children
             with active bacterial infections at the time of diagnosis must be cured prior to
             entry)

          -  Expected poor compliance

          -  Pregnancy

          -  Any other condition that by the judgement of the investigator may be potentially
             harmful to the patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soumya Adhikari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes, basal-bolus, honeymoon, C-peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

